Ahead of the Curve

ORNA’S APPROACH & STRATEGY

Orna Therapeutics is leaving linear thinking behind to create fully engineered oRNATM circular RNAs – an entirely new class of RNA medicines that can realize the full potential of RNA and which is poised to change the way we treat disease. By marrying the power of oRNATM with superior delivery techniques, we are pioneering the next breakthrough in RNA therapeutics.

LIMITLESS POTENTIAL

Orna’s technology has a breadth of applications across multiple disease areas including cancer, regenerative medicine, protein replacement, infectious diseases, and autoimmunity. Our lead program is an in situ CAR therapy that combines oRNATM molecules and proprietary lipid nanoparticles (LNPs) to deliver chimeric antigen receptors (CARs) directly to patient’s immune cells within the body (isCARTM therapy).

Our Team

Creating a new class of therapeutics requires thinking outside the lines. Comprised of a team of skilled scientists, molecular engineers, and industry veterans in addition to a world class Board, we are well-suited for the challenge of bringing the promise of our oRNATM therapeutics to patients.

Thomas Barnes, PhD
Chief Executive Officer
Amy Becker, PhD
Director, Immunology
Nelson Chau, PhD
Senior Vice President, Platform
Claudia Harper, DVM
Senior Vice President, Preclinical Safety
Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology
Thomas Barnes, PhD
CEO, Orna Therapeutics
Thomas Ebeling
Advisor, MPM Capital
Ansbert Gadicke, MD
Chairman of the Board, Co-founder & Managing Director, MPM Capital

NEWS & EVENTS

The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies

September 22, 2022 – The big idea here is that the mRNA revolution that enriched Moderna and BioNTech could benefit a lot from some refinement. If they can keep on failing to fail, Orna has… Read More >
SITC: In situ CAR Therapy Using oRNATM Lipid Nanoparticles Regresses Tumors in Mice

November 11, 2022 Amy M. Becker et al.

International mRNA Conference: Discovery of Translation Initiation Elements Enabled by a Parallel Arrayed Screen of Full-length Viral UTRs in Synthetic Circular RNA

November 8, 2022 Kristen Ott et al.

The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies

September 22, 2022 – The big idea here is that the mRNA revolution that enriched Moderna and BioNTech could benefit a lot from some refinement. If they can keep on failing to fail, Orna has potential to evolve into a leader in the mRNA 2.0 space.